A large-scale trial indicates that the University of Oxford's coronavirus vaccine prevents 70% of people from experiencing symptoms of COVID-19.

The results come after a series of promising vaccine findings following late-stage study readouts from Pfizer-BioNTech and Moderna.

In a CNBC report, AstraZeneca CEO Pascal Soriot said the progress represented an "important milestone" in addressing the global health crisis.

Peter Horby, Professor of Emerging Infectious Diseases and Public Health at the University of Oxford, tweeted: "Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two."

There is also fascinating evidence that indicates that perfecting the dosage might improve safety by up to 90 percent, according to ABC News. In around 10 months, the Oxford researchers carried out the usually decade-long phase of producing a vaccine.

"The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by the virus]," said Prof Sarah Gilbert, the architect of the vaccine.

What Was The Trial Showing?

There were more than 20,000 volunteers interested, according to Telegraph. Half of which are from the United Kingdom, the majority in Brazil. There were 30 cases of Covid in individuals who administered two doses of the vaccine and 101 cases of Covid in individuals who received a dummy injection.

The researchers said the vaccine works out at 70% protection. The safety was 62 percent when two "high doses were provided to volunteers, but this improved to 90 percent when a "low dose accompanied by a high one was given to individuals. Why there is a discrepancy is not obvious.

"We're really pleased with these results," Prof Andrew Pollard, lead prosecutor of the trial, told the BBC. He said the 90 percent data on efficacy are "intriguing" and would mean "we would have a lot more doses to distribute."

Why Is It Working?

The vaccination is a genetically engineered natural cold virus that infects chimpanzees. Experts altered the issue to deter an outbreak of humans from causing it and to hold the blueprints for part of the coronavirus, identified as the spike protein.

Once these blueprints are within the body, they begin developing the coronavirus's spike protein, which the immune system identifies as a hazard and attempts to squash the strain. It now learns what to do as the immune system gets in touch with the virus for good.

Will Coronavirus Vaccines Work by February?

Meanwhile, CNet reported that Microsoft co-founder Bill Gates remains hopeful about the production of coronavirus vaccines, including those produced by AstraZeneca, Johnson & Johnson and Novavax.

"Almost all the vaccines will work and with very high efficacy levels," Gates told CNN's Fareed Zakaria in an interview on Sunday. "I'm optimistic that by February it's very likely that they'll all prove very efficacious and safe."


However, Gates warned that the public should be extra cautious in the next six months. He said the daily mortality toll from the virus would top 2,000 for most of the season. He has addressed research and vaccine delivery concerns but claims those issues would be met.

ALSO READ: Volunteer for Pfizer's Experimental COVID-19 Vaccine Shares Side Effects from Trial

Check out more news and information on COVID-19 on Science Times.